Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03679637
Other study ID # EC/2018/1006
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 28, 2018
Est. completion date December 20, 2019

Study information

Verified date April 2020
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As aphasia is one of the most common and disabling disorders following stroke, in many cases resolving in long-term deficits, it is now thought that intensive aphasia therapy is effective, even in the chronic phase following stroke. However, as intensive aphasia rehabilitation is difficult to achieve in clinical practice, tablet-based aphasia therapies are explored to further facilitate language recovery. Although there is mounting evidence that computer-based treatments are effective, it is also important to assess the feasibility, usability and acceptability of these technologies, especially in the acute phase post stroke. The investigators assume that tablet-based aphasia therapy is a feasible treatment option for patients with aphasia in the acute phase following stroke. The researchers also believe that the specific app that will be used in therapy is user-friendly and that it will be well accepted by this specific patient population.


Description:

The study is a prospective study, with each participant undergoing testing approximately within three days after inclusion in the study (immediately prior to tablet-based aphasia therapy). Based on the results of diagnostic testing (standard of care in the acute phase), therapy will be tailored for each individual. After two short training sessions, patients will independently practice with the app during hospitalisation, guided by a user-friendly instruction sheet. Patients will be encouraged to practice as much as possible, with a minimum of 30 minutes per day. Exercises will be selected by the speech-language therapist based on diagnostic results and will be adjusted for difficulty and type of exercise during treatment based on performance rates. the aim of the study is to investigate the feasibility, usability and acceptability of a tablet-based aphasia therapy in patients with aphasia in the acute phase following stroke.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date December 20, 2019
Est. primary completion date December 20, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosed with aphasia after an ischemic or hemorrhagic stroke

- Maximum 2 weeks post-stroke

- Minimum 18 years old

- A minimum proficient language level of Dutch

- Imaging (CT or MRI) prior to inclusion

- Signed informed consent

Exclusion Criteria:

- Presence of severe psychiatric disorders and/or cognitive disorders that hinder the use of the tablet-based aphasia therapy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Tablet-based aphasia therapy
patients will independently practice with a speech app during hospitalisation

Locations

Country Name City State
Belgium University Hospital, department of neurology Gent

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Ghent

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of a tablet-based aphasia therapy via the recruitment rate Recruitment rate: number of patients enrolled versus total patients meeting study criteria + notation of reasons why patients did not enroll from date of inclusion to date of hospital discharge, assessed up to 20 weeks
Primary Feasibility of a tablet-based aphasia therapy via the retention rate Retention rate: number of patients continuing to use the mobile tablet until the time of discharge + notation of reasons why patients did not continue practicing from date of inclusion to date of hospital discharge, assessed up to 20 weeks
Primary Feasibility of a tablet-based aphasia therapy via the adherence rate, Adherence rate: time patients practiced versus time advised to practice + notation of reasons why patients did not practice the advised time from date of inclusion to date of hospital discharge, assessed up to 20 weeks
Primary Feasibility of a tablet-based aphasia therapy via protocol deviations Notation of any protocol deviations from date of inclusion to date of hospital discharge, assessed up to 20 weeks
Primary Usability of a tablet-based aphasia therapy via a self-prepared usability questionnaire, Self-prepared usability questionnaire: patients will need to fill in a 5 question survey (5-point Likert scale) measuring the usability of a tablet-based therapy. Minimum score is 1 (= totally not agree), maximum score is 5 (= totally agree) date of hospital discharge, an average of 1 week
Primary Usability of a tablet-based aphasia therapy via an observational checklist Self-prepared observational checklist: patients will be observed during a therapy session. Different sub-tasks will be scored for independency on a 3-point scale. Minimum score is 1 (completely dependent), maximum score is 3 (= completely independent) date of hospital discharge, assessed up to 20 weeks
Primary Usability of a tablet-based aphasia therapy via within-task improvements of the app Notation of exercises performed with the app from date of inclusion to date of hospital discharge, assessed up to 20 weeks
Primary Acceptability of a tablet-based aphasia therapy via a vertical VAS-scale for satisfaction Vertical visual anologue scale (VAS) for satisfaction: patients have to indicate their general level of satisfaction post-intervention on a vertical VAS-scale. Minimum score is 0 (= not satisfied), maximum score is 100 (= very satisfied) date of hospital discharge, an average of 1 week
See also
  Status Clinical Trial Phase
Recruiting NCT05378035 - DOAC in Chinese Patients With Atrial Fibrillation
Completed NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Completed NCT03633422 - Evaluation of Stroke Patient Screening
Completed NCT04088578 - VNS-supplemented Motor Retraining After Stroke N/A
Withdrawn NCT04991038 - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients N/A
Not yet recruiting NCT05534360 - Tenecteplase Treatment in Ischemic Stroke Registry
Not yet recruiting NCT04105322 - Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients N/A
Withdrawn NCT05786170 - ERILs Und SNILs Unter SOC N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Completed NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Completed NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS)
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT05760326 - Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients
Completed NCT03618290 - Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke